Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: A prospective longitudinal study

Virology Journal

Volumn 10, Issue 1, 2013, Pages

  Hoffmann, Luísa ^a,b   Ramos, Juliene Antonio ^b,c   De Souza, Elizabeth Valentin ^b   De Araújo Ramos, Ana Lucia ^a   Villela Nogueira, Cristiane Alves ^a   Ürményi, Turán Péter ^a,b   Tanuri, Amilcar ^a   Rondinelli, Edson ^a,b   Silva, Rosane ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Fellow of the National Research Council   (Brazil)

^c INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

Author keywords

Antiviral drugs; Chronic hepatitis C infection; Drug resistance persistency; HCVNS3 protease; Selection pressure

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BRAZILIAN; CHRONIC HEPATITIS; CHRONIC HEPATITIS C; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NS3 PROTEASE GENE; NUCLEOTIDE SEQUENCE; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION;

HEPATITIS C VIRUS;

EID: 84873598160     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-57     Document Type: Article

References (34)

1. WHO: [http://www.who.int/immunization/topics/hepatitis-c/en/].
2. Ray Kim W: Global epidemiology and burden of hepatitis C. Microbes Infect 2002, 4:1219-1225.
3. Alvarado-Mora MV, Moura IM, Botelho-Lima LS, Azevedo RS, Lopes E, Carrilho FJ, Pinho JRR: Distribution and molecular characterization of hepatitis C virus (HCV) genotypes in patients with chronic infection from Pernambuco State, Brazil. Virus Res 2012, 169:8-12.
4. Brazilian Ministry of Health - Disease Notification: [http://dtr2004.saude.gov.br/sinanweb/index.php].
5. Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20:1-16.
6. Codes L, de Freitas LAR, Santos-Jesus R, Vivitski L, Silva LK, Trepo C, Reis MG, Paraná R: Comparative study of hepatitis C virus genotypes 1 and 3 in Salvador, Bahia Brazil. Braz J Infect Dis 2003, 7:409-417.
7. Pereira LMMB, Spinelli V, Ximenes RA, Cavalcanti MS, Melo R, Jucá N, Mizokami M, McFarlane IG: Chronic hepatitis C infection: influence of the viral load, genotypes, and GBV-C/HGV coinfection on the severity of the disease in a Brazilian population. J Med Virol 2002, 67:27-32.
8. Burney T, Dusheiko G: Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti Infect Ther 2011, 9:151-160.
9. Kneteman NM, Howe AYM, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DLJ, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M: HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009, 49:745-752.
10. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M: Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
11. Esteban R, Buti M: Triple therapy with boceprevir or telaprevir for treatment naive HCV patients. Best Pract Res Clin Gastroenterol 2012, 26:445-453.
12. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
13. Garnock-Jones KP: Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection. Drugs 2012, 72:2431-2456.
14. Fontaine H, Pol S: Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. Aquat Toxicol 2011, 35:S59-S63.
15. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
16. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P, SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
17. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA: Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006, 70:28-38.
18. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL: Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008, 198:800-807.
19. Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J: Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008, 370:237-245.
20. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, Mcmahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, et al: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008, 48:1769-1778.
21. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Günthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M: Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009, 49:1069-1082.
22. Lenz O, Verbinnen T, Lin T-I, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA: In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010, 54:1878-1887.
23. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C, ANRS AC11 HCV Group: NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther (Lond) 2011, 16:1093-1102.
24. Forns X, Purcell RH, Bukh J: Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 1999, 7:402-410.
25. Peres-da-Silva A, de Almeida AJ, Lampe E: Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol 2010, 155:807-811.
26. Fonseca-Coronado S, Escobar-Gutierrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruiz-Pacheco JA, Cazares F, Vaughan G: Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. J Clin Microbiol 2012, 50:281-287.
27. Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada S-I, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N: Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int 2011, 6:482-490.
28. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L, Baldanti F: Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol J 2012, 9:245.
29. Chayama K, Hayes CN, Ohishi W, Kawakami Y: Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol 2013, 48:1-12.
30. Inibidores de Protease (Boceprevir e Telaprevir) para o tratamento da Hepatite Crônica C, Brasil: Ministério da Saúde, Secretaria de Ciencia, Tecnologia e Insumos Estratégicos; www.saude.gov.br/sctie.
31. Geneious v. 4.7 created by Biomatters. Available from http://www.geneious.com/.
32. Kuiken C, Combet C, Bukh J, Shin IT, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky J: A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 2006, 44:1355-1361.
33. Fan X, Mao Q, Zhou D, Lu Y, Xing J, Xu Y, Ray SC, Di Bisceglie AM: High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009, 50:1765-1772.
34. Korber B: HIV signature and sequence variation analysis. Dordrecht: Kluwer Academic Publishers; 2000:55-72.